ABx Serving Up Rare Earth Treats for Investors
Among the various projects it currently has on the go, Tasmanian-based miner ABx Group is serving up rare earth treats for investors from its four Tasmanian super magnet metals prospects.
Read More
For WA Minnow NickelX, the Devilish Metal Has Heavenly Appeal
Currently a $10 million market cap tiddler, NickelX hopes to join the WA nickel big league with its acquired Cosmos South project, at the north-east end of the Fraser Range.
Read MoreLittle Green Pharma in Pole Position for European Growth
Known more as an Australian-focused medical cannabis minnow when it listed two years ago, Little Green Pharma now has access to more than half of the addressable EU market.
Read MoreBuying Opportunities Beckon Amid Biotech Bloodbath
The sharp retreat in global biotech valuations is creating rare buying opportunities as investors flee ‘riskier’ sectors on the back of rising rates, dwindling liquidity and heightened geopolitical tensions.
Read More
ABx Group Eyes Aluminium Industry’s Version of AdBlue
Sometimes it’s the supposedly smaller things that can grind industry to a halt, such as the current shortage of the obscure diesel additive AdBlue. ABx Group may just have a solution.
Read MoreArdiden Strives to Shake Up the Industry Gorillas in Canada
Ardiden’s Pickle Lake Gold Project in the gold-rich province of Ontario is just down the road from mines operated by the likes of Evolution Mining, Newmont Mining and Barrick Gold.
Read MoreVIP Gloves Expansion Hands Shareholders Pleasing Returns
For VIP Gloves, a pre-pandemic decision to expand its Malaysian production capacity has proved a positive strategic move capitalising on Malaysia’s dominant global glove manufacturing industry.
Read MoreHow Luxury Escapes Tackled COVID While Other Travel Platforms Took Flight
In his progression from student entrepreneur to founder of one of the world’s fastest growing online travel companies, 41-year-old Melburnian Adam Schwab has tackled plenty of business challenges.
Read MoreMemphasys Taking on One of Humanity’s Most Pressing Issues
Humanity has a profound demographic problem and it’s not overpopulation. On the contrary, men are becoming more infertile and the quality of their sperm is deteriorating, leading to health problems.
Read MoreAlzheimer’s Decision Sends Positive Message to Aussie Biotechs
The US Food and Drug Administration’s approval of a new treatment for Alzheimer’s disease suggests a sea change in the regulator’s attitude to green-lighting novel drugs for difficult-to-treat illnesses.
Read MoreAcquisitive Spirit Takes on Telco and Tech Incumbents
Spirit Technology Solutions has undergone an acquisition and organic sales-fuelled metamorphosis, selling an array of I.T. and telco add-on services to small to mid-sized businesses and not-for-profit clients.
Read MoreHeart Innovator Anteris Takes on Medical Device Giants
It has been a rocky corporate journey for the ASX-listed Anteris Technologies, but with its revolutionary heart technology Anteris has the ticker to be the next Aussie medical device giant.
Read MoreCalima Energy Poised to Expand in Canada’s Best Hydrocarbon Addresses
Tim Boreham has a look at Australian oil and gas developer Calima Energy (ASX: CE1) after its acquisition of Canadian producer Blackspur Oil and recent capital raising.
Read MoreLittle Green Pharma Eyes Global Markets After Federal Regulator Approves State-Of-The-Art Manufacturing Facility
Little Green Pharma has become one of the few Australian cannabis companies with full approvals from both the TGA and the Office of Drug Control.
Read MoreAntisense Eyes A Golden Ticket In The US
Two announcements from drug developer Antisense Therapeutics have raised hopes of an expedited path to market for its novel candidate to treat a genetic muscular disorder that affects only boys and is regressive, fatal, and poorly treated.
Read MoreWith A ‘Ticket To Ride’, Kazia Wows Investors With Its Rare-Cancer Story
Kazia Therapeutics has been trialling its lead drug paxalisib (formerly GDC-0084) to treat the aggressive and complex disease. Paxalisib inhibits a signalling pathway called PI3K which is expressed in 85 per cent to 90 per cent of glioblastoma tumours. After years of quiet development, Kazia in August achieved two key milestones.
Read MoreInvestors Are Listening As Immutep Eyes Revolutionary Cancer Treatments
With Immutep’s largest and most advanced trial in breast cancer patients, AIPAC, the company is running it alone. Otherwise, its clinical activities revolve around partnerships with big pharmaceutical houses, which reduce the risk and cost of big-ticket drug development.
Read MoreNovonix Is Off The Blocks In The Race To Build A ‘Million Mile’ Battery
As a pioneer of advanced battery materials the ASX listed technology house Novonix is playing a key role in cracking the battery equivalent of Roger Bannister’s four-minute-mile in 1954.
Read MoreTurn On, Tune In But Don’t Drop Out: The Pending Boom In Psychedelic Medicines
While local investors are unfamiliar with psychedelic therapy, this is likely to change given the burgeoning interest in North America, where no fewer than 20 companies are actively involved in the field.
Read MoreAre The Banks Perfume Or Poison To Investors?
Assuming the lack of a bad debt apocalypse, the big banks certainly look cheap. But the smaller banks look even cheaper, which suggests there’s better value at the minnow end which is more oriented to mortgages than business lending.
Read MoreThe Gambling Stocks To Punt On Post The Coronavirus Crunch
The age-old notion of Australians betting on anything that crawls has been supported by the behaviour of sports punters during the virus lockdown that has stymied most professional sporting events.
Read MoreLittle Green Pharma Stands Out Amid The Crowded Cannabis Canopy
Little Green Pharma was the first company to produce a home-grown medicinal cannabis product for patient use and it was also the first to export when it became legal to do so. Tim Boreham highlights why the company stands out as a genuine player above a canopy of chancers.
Read MoreBargains For The Brave In The Mining Services Sector
The New Criterion’s Tim Boreham highlights several mining services contractors, large and small, and their potential at this time.
Read MoreTime For Yellowcake’s Day In The Sun?
As followers of uranium would know, there have been plenty of proclamations about an imminent recovery post Fukushima, but they have all turned out to be false dawns. With buyers and sellers trilling from the same song book, is this time different?
Read MoreWill The Listed Sanitiser Stocks Clean Up – Or Clean Out – Investors?
Who said capitalism was dead in the new world order of prolific government handouts? The profit motive is at least alive and kicking in the sexed-up sanitiser sector, as both new and established participants grab on to what’s hopefully a once-in-a-lifetime opportunity.
Read MoreOrganic Growth: The Next Generation Of Stocks Tapping The “Wellness” Boom
Usually referred to in the same breath as health, “wellness” is an amorphous term but that hasn’t stopped investors from flocking to listed exposures to trendy sectors such as organics, artificial meat, probiotics, vitamins and health supplements.
Read MoreThe Business Models Holding Up In The Rout
Beyond the dismal parade of ASX-listed victims ensuing from the corona crisis, a low-profile cluster of stocks is benefiting from the mayhem.
Read MoreThe BNPL Sector Faces Its Sternest Test
The New Criterion’s Tim Boreham assesses what the virus and lockdown mean for Afterpay and other listed buy now, pay later companies.
Read MoreWho (Eventually) Benefits From The New Oil Shock
In more normal times – and nothing is normal at the moment – low oil prices benefit the global economy and stocks such as manufacturers and transport companies. Tim Boreham outlines those Australian companies which stand to benefit from significantly lower energy prices.
Read MoreDo Less Risky Stock Market Exposures Really Exist?
With a sense of raw panic descending on global stock markets, the question is whether there are any truly safe havens in terms of remaining exposed to equities?
Read MoreThe New Cinema Blockbuster As Village Fades To Black
Just as video didn’t kill the radio star, DVDs didn’t snuff out the silver screen and then streaming failed to deliver the mortal blow.
Read MoreASX Biotech Poised To Disrupt Global IVF Market
ASX-listed Memphasys (MEM), has developed a novel device to separate and select sperm more quickly and effectively than the current methods. Dubbed Felix, the device uses electrical fields and membranes to sort the sperm by quality and size.
Read MoreIs There Value In Unloved Coal Stocks?
In adversity lies opportunity and some deep-pocketed investors have recognised that, like the Stone Age, the era of coal won’t end overnight.
Read MoreAll The Dope On Emerald Clinics’ Limp Debut
Having been long on promises but short on deliverables, the ASX listed cannabis sector is taking an evolutionary step from growing the stuff to proving that pot is indeed the healing herb it is meant to be.
Read MoreWhen High-Flying Tech Darlings Return To Earth
The savage share sell down of Nearmap highlights the dangers of investing in tech stocks valued on lusty revenue multiples that leave little room for error. Given that billion-dollar valuations have become common in the sector, no doubt other casualties will emerge as the reporting season unfolds.
Read MoreStocks That Tap The Disaster Zeitgeist
As is the norm, the speculative end of the market moves to its own rhythms and influences. In this vein, here are three ‘special situation’ stocks that plug into the topical anxieties of natural disasters, the coronavirus threat and the security of domestic gas supply.
Read MoreBehind The Victorian Gold Revival
The New Criterion’s Tim Boreham explains why junior gold miners are rushing to secure long abandoned riches in the Bendigo/Ballarat goldfields.
Read MoreBushfire Impact: Affected Stocks
With the prolonged bushfire crisis now abated thanks to the efforts of Mother Nature and tireless firefighters, Tim Boreham ponders the effect of the firestorm on listed equity exposures.
Read MoreIroning Out The Blight Of Money Laundering
It may be cold comfort for shareholders of Westpac and the Commonwealth Bank, but our two biggest banks are not alone when it comes to breaching anti money laundering rules.
Read More